Literature DB >> 21476522

HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution.

Ying Zheng1, Arti B Patel, Vasanthy Narayanaswami, Gregory L Hura, Bo Hang, John K Bielicki.   

Abstract

ATI-5261 is a 26-mer peptide that stimulates cellular cholesterol efflux with high potency. This peptide displays high aqueous solubility, despite having amphipathic α-helix structure and a broad nonpolar surface. These features suggested to us that ATI-5261 may adopt a specific form in solution, having favorable structural characteristics and dynamics. To test this, we subjected ATI-5261 to a series of biophysical studies and correlated self-association with secondary structure and activity. Gel-filtration chromatography and native gel electrophoresis indicated ATI-5261 adopted a discrete self-associated form of low molecular weight at concentrations >1 mg/mL. Formation of a discrete molecular species was verified by small-angle X-ray scattering (SAXS), which further revealed the peptide formed a tetrameric assembly having an elongated shape and hollow central core. This assembly dissociated to individual peptide strands upon dilution to concentrations required for promoting high-affinity cholesterol efflux from cells. Moreover, the α-helical content of ATI-5261 was exceptionally high (74.1 ± 6.8%) regardless of physical form and concentration. Collectively, these results indicate ATI-5261 displays oligomeric behavior generally similar to native apolipoproteins and dissociates to monomers of high α-helical content upon dilution. Optimizing self-association behavior and secondary structure may prove useful for improving the translatability and efficacy of apolipoprotein mimetic peptides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476522      PMCID: PMC3100537          DOI: 10.1021/bi2002955

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  53 in total

Review 1.  Structure and function of apolipoprotein A-I and high-density lipoprotein.

Authors:  J P Segrest; L Li; G M Anantharamaiah; S C Harvey; K N Liadaki; V Zannis
Journal:  Curr Opin Lipidol       Date:  2000-04       Impact factor: 4.776

2.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.

Authors:  G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

3.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

4.  Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice.

Authors:  R K Tangirala; K Tsukamoto; S H Chun; D Usher; E Puré; D J Rader
Journal:  Circulation       Date:  1999-10-26       Impact factor: 29.690

Review 5.  Lipoproteins in the central nervous system.

Authors:  M J Ladu; C Reardon; L Van Eldik; A M Fagan; G Bu; D Holtzman; G S Getz
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

6.  Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity.

Authors:  Geeta Datta; Raquel F Epand; Richard M Epand; Manjula Chaddha; Matthew A Kirksey; David W Garber; Sissel Lund-Katz; Michael C Phillips; Susan Hama; Mohamad Navab; Alan M Fogelman; Mayakonda N Palgunachari; Jere P Segrest; G M Anantharamaiah
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

7.  Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1.

Authors:  Pradeep Natarajan; Trudy M Forte; Berbie Chu; Michael C Phillips; John F Oram; John K Bielicki
Journal:  J Biol Chem       Date:  2004-03-29       Impact factor: 5.157

8.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Authors:  Steven E Nissen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Christopher J Cooper; Muhammad Yasin; Gregory M Eaton; Michael A Lauer; W Scott Sheldon; Cindy L Grines; Stephen Halpern; Tim Crowe; James C Blankenship; Richard Kerensky
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

9.  Inter-molecular coiled-coil formation in human apolipoprotein E C-terminal domain.

Authors:  Nicole Choy; Vincent Raussens; Vasanthy Narayanaswami
Journal:  J Mol Biol       Date:  2003-11-28       Impact factor: 5.469

10.  Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo.

Authors:  YuZhen Zhang; Ilaria Zanotti; Muredach P Reilly; Jane M Glick; George H Rothblat; Daniel J Rader
Journal:  Circulation       Date:  2003-08-04       Impact factor: 29.690

View more
  8 in total

Review 1.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

Review 2.  ABCA1 agonist peptides for the treatment of disease.

Authors:  John K Bielicki
Journal:  Curr Opin Lipidol       Date:  2016-02       Impact factor: 4.776

3.  Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry.

Authors:  Tuyen N Tran; Malathi G Kosaraju; Shiori Tamamizu-Kato; Olayemi Akintunde; Ying Zheng; John K Bielicki; Kent Pinkerton; Koji Uchida; Yuan Yu Lee; Vasanthy Narayanaswami
Journal:  Biochemistry       Date:  2014-01-08       Impact factor: 3.162

Review 4.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

5.  Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro.

Authors:  Anouar Hafiane; John K Bielicki; Jan O Johansson; Jacques Genest
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship.

Authors:  Mark T Lek; Siobanth Cruz; Nnejiuwa U Ibe; Wendy H J Beck; John K Bielicki; Paul M M Weers; Vasanthy Narayanaswami
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

7.  Apolipoprotein A1 mimetic peptide ATI-5261 reverses arterial stiffness at late pregnancy and early postpartum in a COMT-/- mouse model of preeclampsia.

Authors:  Shutan Liao; Hao Wu; Ruiying Chen
Journal:  Clin Hypertens       Date:  2018-09-15

8.  HDL, Atherosclerosis, and Emerging Therapies.

Authors:  Anouar Hafiane; Jacques Genest
Journal:  Cholesterol       Date:  2013-05-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.